Early Outcomes After Initiation of Faricimab for Neovascular Age-Related Macular Degeneration
Ferhina S. Ali, David Tabano, Durga S. Borkar, Theodore Leng, Vincent Garmo, Ayesha Ahmed, Rachel A. Myers, Jacqueline K. Shaia, Giulio Barteselli, Rishi P. Singh
Abstract
Background and Objective This study assessed treatment patterns and early outcomes among patients with neovascular age-related macular degeneration (nAMD) initiating faricimab in routine clinical practice in the United States. Patients and Methods FARETINA-AMD is a retrospective study among patients with nAMD initiating faricimab from February 2022 to June 2023 identified from the US IRIS ® Registry. Results Included were 21,508 patients previously treated with anti-vascular endothelial growth factor (anti-VEGF) (25,784 eyes) and 1,836 treatment-naïve patients (1,982 eyes) with nAMD. Among previously treated eyes, visual acuity remained stable with faricimab. In treatment-naïve eyes, mean ± SD visual acuity improved from 56.7 ± 24.1 letters at index to 61.4 ± 22.3 after faricimab injection 4 ( P < 0.01). Mean ± SD central subfield thickness improved from 315.2 ± 80.0 (index) to 264.9 ± 60.1 μm (injection 4) in treatment-naïve eyes and 296.2 ± 95.5 to 273.0 ± 81.4 μm in previously treated eyes (both P < 0.01). Conclusions Among patients with nAMD receiving faricimab, visual acuity improved in treatment-naïve eyes, and both previously treated and treatment-naïve eyes experienced anatomical improvement.